BACKGROUND: We sought to evaluate the prognostic performance of the CHADS(2) score for prediction of ischemic stroke/transient ischemic attack (TIA) in subjects with coronary heart disease (CHD) without atrial fibrillation (AF). METHODS: In 916 nonanticoagulated outpatients with stable CHD and no AF by baseline electrocardiogram, we calculated CHADS(2) scores (congestive heart failure, hypertension, age ≥75 years, diabetes [1 point each], and prior stroke or TIA [2 points]). The primary outcome was time to ischemic stroke or TIA over a mean follow-up of 6.4 ± 2.3 years. RESULTS: Over 5,821 person-years of follow-up, 40 subjects had an ischemic stroke/TIA (rate 0.69/100 person-years, 95% CI 0.50-0.94). Compared with subjects with low (0-1) CHADS(2) scores, those with intermediate (2-3) and high (4-6) CHADS(2) scores had an increased rate of stroke/TIA, even after adjustment for age, tobacco, antiplatelet therapy, statins, and angiotensin inhibitors (CHADS(2) score 2-3: HR 2.4, 95% CI 1.1-5.3, P = .03; CHADS(2) score 4-6: HR 4.0, 95% CI 1.5-10.6, P = .006). Model discrimination (c-statistic = 0.65) was comparable with CHADS(2) model fit in published AF-only cohorts. CONCLUSIONS: The CHADS(2) score predicts ischemic stroke/TIA in subjects with stable CHD and no baseline AF. The event rate in non-AF subjects with high CHADS(2) scores (5-6) was comparable with published rates in AF patients with moderate CHADS(2) scores (1-2), a population known to derive benefit from stroke prevention therapies. These findings should inform efforts to determine whether stroke prevention therapies or screening for silent AF may benefit subjects with stable CHD and high CHADS(2) scores.
BACKGROUND: We sought to evaluate the prognostic performance of the CHADS(2) score for prediction of ischemic stroke/transient ischemic attack (TIA) in subjects with coronary heart disease (CHD) without atrial fibrillation (AF). METHODS: In 916 nonanticoagulated outpatients with stable CHD and no AF by baseline electrocardiogram, we calculated CHADS(2) scores (congestive heart failure, hypertension, age ≥75 years, diabetes [1 point each], and prior stroke or TIA [2 points]). The primary outcome was time to ischemic stroke or TIA over a mean follow-up of 6.4 ± 2.3 years. RESULTS: Over 5,821 person-years of follow-up, 40 subjects had an ischemic stroke/TIA (rate 0.69/100 person-years, 95% CI 0.50-0.94). Compared with subjects with low (0-1) CHADS(2) scores, those with intermediate (2-3) and high (4-6) CHADS(2) scores had an increased rate of stroke/TIA, even after adjustment for age, tobacco, antiplatelet therapy, statins, and angiotensin inhibitors (CHADS(2) score 2-3: HR 2.4, 95% CI 1.1-5.3, P = .03; CHADS(2) score 4-6: HR 4.0, 95% CI 1.5-10.6, P = .006). Model discrimination (c-statistic = 0.65) was comparable with CHADS(2) model fit in published AF-only cohorts. CONCLUSIONS: The CHADS(2) score predicts ischemic stroke/TIA in subjects with stable CHD and no baseline AF. The event rate in non-AF subjects with high CHADS(2) scores (5-6) was comparable with published rates in AFpatients with moderate CHADS(2) scores (1-2), a population known to derive benefit from stroke prevention therapies. These findings should inform efforts to determine whether stroke prevention therapies or screening for silent AF may benefit subjects with stable CHD and high CHADS(2) scores.
Authors: David A Fitzmaurice; F D Richard Hobbs; Sue Jowett; Jonathon Mant; Ellen T Murray; Roger Holder; J P Raftery; S Bryan; Michael Davies; Gregory Y H Lip; T F Allan Journal: BMJ Date: 2007-08-02
Authors: Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; Jean-Yves Le Heuzey; G Neal Kay; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; Samuel Wann; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffery L Anderson; Elliott M Antman; Jonathan L Halperin; Sharon Ann Hunt; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Silvia G Priori; Jean-Jacques Blanc; Andrzej Budaj; A John Camm; Veronica Dean; Jaap W Deckers; Catherine Despres; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; Joao Morais; Ady Osterspey; Juan Luis Tamargo; José Luis Zamorano Journal: Circulation Date: 2006-08-15 Impact factor: 29.690
Authors: Linda R Peterson; Alan D Waggoner; Lisa de las Fuentes; Kenneth B Schechtman; Janet B McGill; Robert J Gropler; Victor G Dávila-Román Journal: J Am Soc Echocardiogr Date: 2006-06 Impact factor: 5.251
Authors: Margaret C Fang; Alan S Go; Yuchiao Chang; Leila Borowsky; Niela K Pomernacki; Daniel E Singer Journal: J Am Coll Cardiol Date: 2008-02-26 Impact factor: 24.094
Authors: Daniel E Singer; Gregory W Albers; James E Dalen; Margaret C Fang; Alan S Go; Jonathan L Halperin; Gregory Y H Lip; Warren J Manning Journal: Chest Date: 2008-06 Impact factor: 9.410
Authors: Teresa S M Tsang; Marion E Barnes; Walter P Abhayaratna; Steven S Cha; Bernard J Gersh; Andrew P Langins; Tammy D Green; Kent R Bailey; Yoko Miyasaka; James B Seward Journal: Am J Cardiol Date: 2006-02-03 Impact factor: 2.778
Authors: Sergio Conti; James A Reiffel; Bernard J Gersh; Peter R Kowey; Rolf Wachter; Jonathan L Halperin; Rachelle E Kaplon; Erika Pouliot; Atul Verma Journal: J Atr Fibrillation Date: 2017-02-28
Authors: Jone Vencloviene; Ruta Marija Babarskiene; Paulius Dobozinskas; Audrius Dedele; Kristina Lopatiene; Nijole Ragaisyte Journal: Environ Sci Pollut Res Int Date: 2017-05-10 Impact factor: 4.223
Authors: Richard Whitlock; Jeff S Healey; Stuart J Connolly; Julie Wang; Matthew R Danter; Jack V Tu; Richard Novick; Stephen Fremes; Kevin Teoh; Vikas Khera; Salim Yusuf Journal: CMAJ Date: 2014-07-21 Impact factor: 8.262